Physician profile
Steven A Bramwit
NPI 1730183146
$2,953.86
in general payments reported to CMS, 2019-2025
20 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $327 · 2021: $583 · 2022: $396 · 2023: $306 · 2024: $352 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $936.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $559.70 | 2021-2025 | Nucala |
| Acclarent, INC | $275.42 | 2019-2021 | |
| Intersect Ent, INC. | $246.35 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $191.51 | 2019 | |
| Aerin Medical INC. | $167.31 | 2025 | |
| Stryker Corporation | $161.43 | 2020-2024 | Xpress Loprofile |
| Genzyme Corporation | $97.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.85 | 2019 | |
| Integra Lifesciences Corporation | $45.44 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $36.86 | 2022-2024 | Dupixent |
| Boston Scientific Corporation | $34.66 | 2023 | |
| Neurent Medical Limited | $28.86 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Medtronic, INC. | $22.30 | 2024 | Propel |
| Ascendis Pharma Endocrinology INC | $20.75 | 2025 | Yorvipath |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Freudenberg Medical, LLC | $19.59 | 2024 | |
| Smith+Nephew, INC. | $17.35 | 2021 | |
| Photonicare INC | $16.97 | 2025 | Otosight Middle Ear Scope |
| Alk-Abello, INC | $15.36 | 2020 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bramwit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.